- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06196242
Deep Brain Stimulation Lead Localization After Implantation
December 25, 2023 updated by: Luming Li, Tsinghua University
Research on Lead Localization for Deep Brain Stimulation After Implantation
Deep brain stimulation (DBS) is an effective treatment for a variety of neurological and psychiatric disorders, with more than 200,000 patients implanted with DBS devices worldwide.
Parkinson's disease is one of the typical indications.The clinical outcomes of DBS depends on the accurate implantation of the lead, and the identification of the lead locations is the basis for evaluating the effectiveness of the treatment.
The aim of this study is to localize the implantation position of the lead based on postoperative MRI images and to reconstruct the relative spatial relationship between the lead and the stimulation target.
By comparing with the lead position identified based on postoperative CT, this study will evaluate the accuracy of identifying the DBS lead position directly from MRI.
This study may help to optimise the stimulation parameters and investigate the best stimulation targets for DBS patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Feng Zhang, Ph.D.
- Phone Number: 86-010-62794952
- Email: zhang-f@mail.tsinghua.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100084
- Recruiting
- National Engineering Research Center of Neuromodulation
-
Principal Investigator:
- Luming Li, Ph.D.
-
Contact:
- Feng Zhang, Ph.D.
- Phone Number: 86-010-62794952
- Email: zhang-f@mail.tsinghua.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Parkinson's disease patients with DBS devices, DBS implanted for at least 1 month.
- Ability to tolerate DBS turn-off for at least 30 minutes.
- DBS devices do not contain the ferromagnetic material.
- The patients can fully understand the content of the trial and sign the informed consent form.
- Able to comply to the requirements of this study.
Exclusion Criteria:
- Presence of other concomitant diseases that have or require implantation of pacemakers, defibrillators, cochlear implants, or other neurostimulation devices.
- Patients who are abnormally sensitive to temperature or allergic to heat.
- Patients with severe psychiatric disorders or cognitive impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DBS lead localization
Participates will receive a head MRI anc CT scan.
The stimulation target and the related neural nuclei will be reconstructed using MRI images.
The spatial position of the implanted lead will be identified with MRI and CT.
Through comparing with the identified lead position by CT, the accuracy of lead localization by MRI will be evaluated.
|
An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices. An CT plain scan of the head in about 10 minutes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lead position
Time Frame: 1 day
|
The accuracy of the lead localization will be evaluated by the distance between the identified position of the lead electrode and the center of the reconstructed stimulation target.
The result of lead localization by CT will be used as the reference.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 10, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
December 25, 2023
First Submitted That Met QC Criteria
December 25, 2023
First Posted (Actual)
January 9, 2024
Study Record Updates
Last Update Posted (Actual)
January 9, 2024
Last Update Submitted That Met QC Criteria
December 25, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LeadLocMRI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on MRI and CT scan
-
Amsterdam UMC, location VUmcMRIguidance B.V.CompletedSinusitis | Hearing Loss | Head and Neck Tumor | Cholesteatoma | Imaging of Bony Structures of the Head (Various Conditions)Netherlands
-
West China HospitalRecruiting
-
London Health Sciences CentreCompleted
-
M.D. Anderson Cancer CenterNot yet recruitingBrain Malignancies | PseudoprogressionUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingReverse Shoulder ProsthesisFrance
-
University Hospitals Bristol and Weston NHS Foundation...Bosum Buddies; Friends of the Bristol Haematology and Oncology CentreTerminated
-
University of EdinburghCompletedMyocardial Infarction | Fibrosis | Neovascularization, PathologicUnited Kingdom
-
Medical University InnsbruckRuth Kröss, MD EDAIC; Glodny Bernhard, MD PD Assoc. Prof.; Laura Trefzer, Cand... and other collaboratorsCompletedEmergencies | Bone Infection | Infusion Site InjuryAustria
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedStroke | Hemiplegia